Back to News
Market Impact: 0.25
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
Source: globenewswire.com
Healthcare & Biotech
Ongoing Phase 1b studies of gamgertamig suggest patients with autoimmune cytopenias may retain remission after B-cell reconstitution, without background therapy. The findings are described as consistent with an “immune reset”; no numerical efficacy results or study size are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- How Abdul El-Sayed would build Medicare for All, from a wealth tax to a Fed-style governing board
- BillionToOne SVP John ten Bosch sells $320,723 in stock
- CVS Plans to Break Up $117 Billion Healthcare Conglomerate
- Sight Sciences earnings missed by $0.48, revenue topped estimates
- Novo raises full-year outlook as Wegovy sales impress
- Stifel raises Zimmer Biomet stock price target on strong quarter
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Quartr Alternatives for Institutional Research Teams